



SAJAF040692321

CLIENT CODE: C000138364
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL LTD

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

PATIENT ID:

AHMEDABAD, 380015

GUJRAT, INDIA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

PATIENT NAME: SAJANA KUMARI

ACCESSION NO: 0321VG003216 AGE: 30 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

#### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

RI OOD	COUNTS	FDTA	WHOLE	RI OOD

HEMOGLOBIN	11.8	Low	12.0 - 15.0	g/dL
				<i>J,</i>
RED BLOOD CELL COUNT	4.36		3.8 - 4.8	mil/µL
WHITE BLOOD CELL COUNT	5.59		4.0 - 10.0	thou/µL
PLATELET COUNT	180		150 - 410	thou/µL
RBC AND PLATELET INDICES				
HEMATOCRIT	37.1		36.0 - 46.0	%
MEAN CORPUSCULAR VOL	85.0		83.0 - 101.0	fL
MEAN CORPUSCULAR HGB.	27.0		27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION	31.8		31.5 - 34.5	g/dL
MENTZER INDEX	19.5			
RED CELL DISTRIBUTION WIDTH	14.4	High	11.6 - 14.0	%
MEAN PLATELET VOLUME	10.4		6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT - NLR				
SEGMENTED NEUTROPHILS	45		40 - 80	%
ABSOLUTE NEUTROPHIL COUNT	2.52		2.0 - 7.0	thou/µL
LYMPHOCYTES	48	High	20 - 40	%
ABSOLUTE LYMPHOCYTE COUNT	2.68		1.0 - 3.0	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	0.9			
EOSINOPHILS	2		1.0 - 6.0	%
ABSOLUTE EOSINOPHIL COUNT	0.11		0.02 - 0.50	thou/µL
MONOCYTES	5		2.0 - 10.0	%
ABSOLUTE MONOCYTE COUNT	0.28		0.2 - 1.0	thou/µL
BASOPHILS	0		0 - 1	%
ABSOLUTE BASOPHIL COUNT	0.00	Low	0.02 - 0.10	thou/µL

DIFFERENTIAL COUNT PERFORMED ON: EDTA SMEAR

**MORPHOLOGY** 

RBC NORMOCYTIC NORMOCHROMIC
WBC RELATIVE LYMPHOCYTOSIS

PLATELETS ADEQUATE

REMARKS NO PREMATURE CELLS ARE SEEN. MALARIAL PARASITES ARE NOT

DETECTED.

# **ERYTHRO SEDIMENTATION RATE, BLOOD**









SAJAF040692321

**CLIENT CODE:** C000138364 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

GRAND MALL, OPPOSITE SBI ZONAL OFFICE,SM ROAD, AMBAWADI, AHMEDABAD, 380015

PATIENT ID:

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

**PATIENT NAME: SAJANA KUMARI** 

ACCESSION NO: **0321VG003216** AGE: 30 Years SEX: Female ABHA NO:

RECEIVED: 23-07-2022 10:47 25-07-2022 16:28 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

GLUCOSE, FASTING, PLASMA   92   74 - 99   mg/dL	Test Report Status	<u>Final</u>	Results		Biological Reference Interv	al Units
March   Marc	SEDIMENTATION RATE	(ESR)	03		0 - 20	mm at 1 hr
GLYCOSYLATED   HEMOGLOBIN   EDTA WHOLE BLOOD	GLUCOSE, FASTING,	PLASMA				
Section   Sect	GLUCOSE, FASTING, P	LASMA	92		74 - 99	mg/dL
Pre-diabetics: 5.7 - 6.4   Diabetics: > 0 r = 6.5   ADA Target: 7.0   Action suggested: > 8.0   MEAN PLASMA GLUCOSE   88.2   < 116.0   mg/dL	GLYCOSYLATED HEM	OGLOBIN, EDTA WHO	DLE BLOOD			
GLUCOSE, POST-PRANDIAL, PLASMA   88   70 - 140   mg/dL	GLYCOSYLATED HEMO	GLOBIN (HBA1C)	4.7		Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0	%
CORONARY RISK PROFILE (LIPID PROFILE), SERUM.   CHOLESTEROL   137   Desirable: < 200   BorderlineHigh: 200 - 239   High: > or = 240   Position	MEAN PLASMA GLUCOS	SE	88.2		< 116.0	mg/dL
CORONARY RISK PROFILE (LIPID PROFILE), SERUM.           CHOLESTEROL         137         Desirable: < 200 mg/dL BorderlineHigh: 200 - 239 High: > or = 240         mg/dL BorderlineHigh: 150 - 199 High: > or = 240           TRIGLYCERIDES         75         Desirable: < 150 mg/dL BorderlineHigh: 150 - 199 High: 200 - 499 Very High: > or = 500         mg/dL Province Pr	GLUCOSE, POST-PRA	NDIAL, PLASMA				
CHOLESTEROL       137       Desirable: < 200 moder lineHigh: 200 - 239 moder lineHigh: 200 - 239 moder lineHigh: > or = 240       Moder lineHigh: 200 - 239 moder lineHigh: 150 moder lineHigh: 150 - 199 moder lineHigh: 150 - 199 moder lineHigh: 200 - 499 moder lineHigh: > or = 500         HDL CHOLESTEROL       51       < 40 Low moder line line line line line line line line	GLUCOSE, POST-PRAN	DIAL, PLASMA	88		70 - 140	mg/dL
BorderlineHigh: 200 - 239   High: > or = 240	CORONARY RISK PR	OFILE (LIPID PROFIL	E), SERUM.			
BorderlineHigh: 150 - 199   High: 200 - 499   Very High: > or = 500	CHOLESTEROL		137		BorderlineHigh: 200 - 239	mg/dL
HDL CHOLESTEROL   51	TRIGLYCERIDES		75		Desirable: < 150 BorderlineHigh: 150 - 199 High: 200 - 499	mg/dL
NearOptimal/AboveOptimal: 100 - 129   BorderlineHigh: 130 - 159   High: 160 - 189   VeryHigh: = 190     NON HDL CHOLESTEROL   86   Desirable: Less than 130   mg/dL   Above Desirable: 130 - 159   Borderline High: 160 - 189   High: 190 - 219   Very high: > or = 220     CHOL/HDL RATIO   2.7   Low   3.30 - 4.40   LDL/HDL RATIO   1.5   0.5 - 3.0	HDL CHOLESTEROL		51		< 40 Low	mg/dL
NON HDL CHOLESTEROL       86       Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220         CHOL/HDL RATIO       2.7       Low 3.30 - 4.40         LDL/HDL RATIO       1.5       0.5 - 3.0	DIRECT LDL CHOLESTE	EROL	78		NearOptimal/AboveOptimal: 100 - 129 BorderlineHigh: 130 - 159 High: 160 - 189	mg/dL
CHOL/HDL RATIO         2.7         Low         3.30 - 4.40           LDL/HDL RATIO         1.5         0.5 - 3.0	NON HDL CHOLESTER	DL	86		Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219	mg/dL
	CHOL/HDL RATIO		2.7	Low		
VERY LOW DENSITY LIPOPROTEIN 15.0 < or = 30.0 mg/dL	LDL/HDL RATIO		1.5		0.5 - 3.0	
	VERY LOW DENSITY LI	POPROTEIN	15.0		< or = 30.0	mg/dL









SAJAF040692321

CLIENT CODE: C000138364
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

ACCESSION NO: 0321VG003216

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL LTD

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

PATIENT ID:

AHMEDABAD, 380015

GUJRAT, INDIA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

ABHA NO:

PATIENT NAME: SAJANA KUMARI

AGE: 30 Years

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

SEX: Female

#### Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction, the test includes five basic parameters: total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol and Non HDL cholesterol.

- 1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.
- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body.
  - Both quantity and composition of the diet impact on plasma triglyceride concentrations
  - Elevations in TG levels are the result of overproduction and impaired clearance.
  - High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.
- 3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL
- 4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.
- 5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies.

Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

# Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

	Risk Category				
Extreme risk group	group A.CAD with > 1 feature of high risk group				
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease				
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia				
High Risk  1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque					
Moderate Risk	2 major ASCVD risk factors				
Low Risk	0-1 major ASCVD risk factors				
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors					
1. Age > or = 45 years in males and > or = 55 years in females		3. Current Cigarette smoking or tobacco use			
2. Family history of premature ASCVD		4. High blood pressure			
5 Low HDL					









CLIENT CODE: C000138364
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156 SRL LTD

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

PATIENT NAME: SAJANA KUMARI PATIENT ID: SAJAF040692321

ACCESSION NO: 0321VG003216 AGE: 30 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

## Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30 )	< 80 (Optional goal <or 60)<="" =="" td=""><td>&gt;OR = 50</td><td>&gt;OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months

## References:

Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

# LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.68		Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.28	High	Upto 0.2	mg/dL
BILIRUBIN, INDIRECT	0.40		0.00 - 1.00	mg/dL
TOTAL PROTEIN	7.0		6.4 - 8.3	g/dL
ALBUMIN	4.9		3.5 - 5.2	g/dL
GLOBULIN	2.1		2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	2.3	High	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	16		0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	10		0 - 33	U/L
ALKALINE PHOSPHATASE	47		35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	9		5 - 36	U/L
LACTATE DEHYDROGENASE	142		135 - 214	U/L
SERUM BLOOD UREA NITROGEN				
BLOOD UREA NITROGEN	7		6 - 20	mg/dL
CREATININE, SERUM				
CREATININE	0.51	Low	0.60 - 1.10	mg/dL
BUN/CREAT RATIO				
BUN/CREAT RATIO	13.73		5.0 - 15.0	



Page 4 Of 12





**CLIENT CODE:** C000138364 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

GRAND MALL, OPPOSITE SBI ZONAL OFFICE,SM ROAD, AMBAWADI, AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

**PATIENT NAME: SAJANA KUMARI** PATIENT ID: SAJAF040692321

ACCESSION NO: **0321VG003216** AGE: 30 Years SEX: Female ABHA NO:

RECEIVED: 23-07-2022 10:47 25-07-2022 16:28 DRAWN: REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units	
LIDIC ACID SEDIM				
URIC ACID, SERUM URIC ACID	2.8	2.4 - 5.7	mg/dL	
ELECTROLYTES (NA/K/CL), SERUM	2.0	2.4 3.7	mg/ac	
SODIUM	140.8	136- 145	mmol/L	
POTASSIUM	4.41	3.50- 5.10	mmol/L	
CHLORIDE	105.6	98 - 107	mmol/L	
PHYSICAL EXAMINATION, URINE	103.0	30 107	THITIOI, E	
COLOR	Yellow			
APPEARANCE	Clear			
SPECIFIC GRAVITY	1.015	1.003 - 1.035		
CHEMICAL EXAMINATION, URINE	11013	11003 11033		
PH	7.0	4.7 - 7.5		
PROTEIN	NOT DETECTED	NOT DETECTED		
GLUCOSE	NOT DETECTED	NOT DETECTED		
KETONES	NOT DETECTED	NOT DETECTED		
BLOOD	NOT DETECTED	NOT DETECTED		
BILIRUBIN	NOT DETECTED	NOT DETECTED		
UROBILINOGEN	NORMAL	NORMAL		
NITRITE	NOT DETECTED	NOT DETECTED		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED		
MICROSCOPIC EXAMINATION, URINE				
PUS CELL (WBC'S)	1-2	0-5	/HPF	
EPITHELIAL CELLS	2-3	0-5	/HPF	
ERYTHROCYTES (RBC'S)	NOT DETECTED	NOT DETECTED	/HPF	
CASTS	NOT DETECTED			
CRYSTALS	NOT DETECTED			
BACTERIA	NOT DETECTED	NOT DETECTED		
YEAST	NOT DETECTED	NOT DETECTED		
REMARKS		MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT ON CENTRIFUGED URINARY SEDIMENT.		
THYROID PANEL, SERUM				
Т3	113.6	80.00 - 200.00	ng/dL	
T4	9.17	5.10 - 14.10	μg/dL	
TSH 3RD GENERATION	3.410	0.270 - 4.200	μIU/mL	
DADANTOOL AOUL CHEAD				











CLIENT CODE: C000138364
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL LTD

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

PATIENT NAME: SAJANA KUMARI PATIENT ID: SAJAF040692321

ACCESSION NO: 0321VG003216 AGE: 30 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

SPECIMEN TYPE TWO UNSTAINED CERVICAL SMEARS RECEIVED

REPORTING SYSTEM 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SPECIMEN ADEQUACY SATISFACTORY

MICROSCOPY SMEARS SHOW PREDOMINANTLY SUPERFICIAL AND INTERMEDIATE

SQUAMOUS CELLS AGAINST CLEAR BACKGROUND. ENDOCERVICAL

CELLS NOT SEEN.

NO EVIDENCE OF DYSPLASIA OR MALIGNANT CELLS SEEN ON SMEARS.

INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Comments

Please note PAP smear is a screening procedure for cervical cancer with inherent false negative result, hence should be interpreted with caution.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B
RH TYPE POSITIVE

**XRAY-CHEST** 

IMPRESSION NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO TMT:- NORMAL

ECG

ECG "T" WAVE INVERSION IN V3, LOW VOLTAGE

**MEDICAL HISTORY** 

RELEVANT PRESENT HISTORY NOT SIGNIFICANT

RELEVANT PAST HISTORY P/H/O RIGHT FALLOPIAN TUBE REMOVAL 2 YEARS BACK

RELEVANT PERSONAL HISTORY NOT SIGNIFICANT

MENSTRUAL HISTORY (FOR FEMALES)

LMP (FOR FEMALES)

OBSTETRIC HISTORY (FOR FEMALES)

RELEVANT FAMILY HISTORY

OCCUPATIONAL HISTORY

HISTORY OF MEDICATIONS

REGULAR

04/07/2022

G1,P0,A1,L2

NOT SIGNIFICANT

NOT SIGNIFICANT

FERTILITY TREATMENT

**ANTHROPOMETRIC DATA & BMI** 

HEIGHT IN METERS 1.52 mts WEIGHT IN KGS. 51.4 Kgs









SAJAF040692321

CLIENT CODE: C000138364
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL LTD

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

PATIENT ID:

AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

PATIENT NAME: SAJANA KUMARI

ACCESSION NO: 0321VG003216 AGE: 30 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BMI 22 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

**GENERAL EXAMINATION** 

MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE NORMAL GENERAL APPEARANCE / NUTRITIONAL STATUS **HEALTHY BUILT / SKELETAL FRAMEWORK AVERAGE** FACIAL APPEARANCE NORMAL SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB NORMAL **NECK** NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

TEMPERATURE NORMAL PULSE 66/MIN RESPIRATORY RATE NORMAL

**CARDIOVASCULAR SYSTEM** 

BP 110/70 MM HG mm/Hg

(SITTING) NORMAL

PERICARDIUM NORMAL APEX BEAT NORMAL

HEART SOUNDS S1, S2 HEARD NORMALLY

MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST

MOVEMENTS OF CHEST

BREATH SOUNDS INTENSITY

NORMAL

NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

**PER ABDOMEN** 

APPEARANCE NORMAL LIVER NOT PALPABLE



Page 7 Of 12





**CLIENT CODE:** C000138364 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL LTD

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

PATIENT NAME: SAJANA KUMARI PATIENT ID: SAJAF040692321

ACCESSION NO: 0321VG003216 AGE: 30 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPLEEN NOT PALPABLE

**CENTRAL NERVOUS SYSTEM** 

HIGHER FUNCTIONS NORMAL
CRANIAL NERVES NORMAL
CEREBELLAR FUNCTIONS NORMAL
SENSORY SYSTEM NORMAL
MOTOR SYSTEM NORMAL
REFLEXES NORMAL

**MUSCULOSKELETAL SYSTEM** 

SPINE NORMAL JOINTS NORMAL

**BASIC EYE EXAMINATION** 

DISTANT VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT
DISTANT VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT
NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT
NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT

COLOUR VISION NORMAL

**SUMMARY** 

RELEVANT HISTORY NOT SIGNIFICANT
RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT
RELEVANT LAB INVESTIGATIONS HEMOGLOBIN:- LOW

RELEVANT NON PATHOLOGY DIAGNOSTICS ECG:- "T" WAVE INVERSION IN V3, LOW VOLTAGE

USG ABDOMEN:- ANTEVERTED UTERUS

REMARKS / RECOMMENDATIONS 1) HEMOGLOBIN:- LOW

ADV:- TAKE MORE DIETARY IRON

2) ECG:- "T" WAVE INVERSION IN V3, LOW VOLTAGE

ADV:- S. TSH LEVEL, 2D ECHO

#### Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

GENERAL PHYSICIAN:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST:- DR. KALPANA MODI (M.D.RADIOLOGY) // DR. SAHIL N SHAH (M.D.RADIOLOGY)









SAJAF040692321

**CLIENT CODE:** C000138364

**CLIENT'S NAME AND ADDRESS:** ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL LTD

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

**PATIENT NAME: SAJANA KUMARI** 

PATIENT ID:

0321VG003216 AGE: 30 Years SEX: Female ABHA NO: ACCESSION NO:

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

#### Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-

Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT - NLRThe optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope. ERYTHRO SEDIMENTATION RATE, BLOOD-

Erythrocyte sedimentation rate (ESR) is a non - specific phenomena and is clinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactants. The ESR is increased in pregnancy from about the 3rd month and returns to normal by the 4th week post partum. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (0 -1mm) in polycythaemia, hypofibrinogenemia or congestive cardiac failure and when there are abnormalities of the red cells such as poikilocytosis, spherocytosis or sickle cells.

- Nathan and Oski's Haematology of Infancy and Childhood, 5th edition
   Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin
- 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th Edition" GLUCOSE, FASTING, PLASMA-

ADA 2021 guidelines for adults, after 8 hrs fasting is as follows: Pre-diabetics: 100 - 125 mg/dL Diabetic: > or = 126 mg/dL

GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOODGlycosylated hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the red blood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood, the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks.

Any condition that alters the life span of the red blood cells has the potential to alter the GHb level. Samples from patients with hemolytic anemias will exhibit decreased glycated hemoglobin values due to the shortened life span of the red cells. This effect will depend upon the severity of the anemia. Samples from patients with polycythemia or post-splenectomy may exhibit increased glycated hemoglobin values due to a somewhat longer life span of the red cells.

Glycosylated hemoglobins results from patients with HbSS, HbCC, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia, increased red cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. In these conditions, alternative forms of

testing such as glycated serum protein (fructosamine) should be considered.
"Targets should be individualized; More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of

diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

#### References

- 1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R.Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006,
- 2. Forsham PH. Diabetes Mellitus: A rational plan for management. Postgrad Med 1982, 71,139-154.
- 3. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184. GLUCOSE, POST-PRANDIAL, PLASMA-ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5 minutes.

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give billitubilits a velowishi pignetic foldulu in bile and its a breakdown product of normal netties catabolism. Billitubilits is excreted in bile and time, and elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT



Page 9 Of 12





SAJAF040692321

**CLIENT CODE:** C000138364

**CLIENT'S NAME AND ADDRESS:** ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT **NEW DELHI 110030 DELHI INDIA** 8800465156

ACCESSION NO:

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

PATIENT ID:

AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

**PATIENT NAME: SAJANA KUMARI** 

0321VG003216 AGE: 30 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SFLF CLIENT PATIENT ID:

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or c,Multiple myeloma,Waldenstrom's disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

SERUM BLOOD UREA NITROGEN-Causes of Increased levels

Pre renal

- High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal
   Renal Failure

· Malignancy, Nephrolithiasis, Prostatism

Causes of decreased levels

- Liver disease
- SIADH.

CREATININE, SERUM-

Higher than normal level may be due to:

- Blockage in the urinary tract
  Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- · Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy URIC ACID, SERUM-

Causes of Increased levels

- Dietary
   High Protein Intake.
- Prolonged Fasting,
- Rapid weight loss.

Gout

Lesch nyhan syndrome.

Type 2 DM. Metabolic syndrome

Causes of decreased levels

- Low Zinc Intake
- Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluids
  Limit animal proteins
  High Fibre foods
- Vit C Intake

• Antioxidant rich foods ELECTROLYTES (NA/K/CL), SERUM-

Sodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt Chloride is decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting,



Page 10 Of 12 Scan to View Report





SAJAF040692321

**CLIENT CODE:** C000138364

**CLIENT'S NAME AND ADDRESS:** ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

ACCESSION NO:

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

PATIENT ID:

AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

**PATIENT NAME: SAJANA KUMARI** 

0321VG003216 AGE: 30 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 23-07-2022 10:47 REPORTED: 25-07-2022 16:28

REFERRING DOCTOR: SFLF CLIENT PATIENT ID:

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

MICROSCOPIC EXAMINATION, URINE-

Routine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders

Protein: Elevated proteins can be an early sign of kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain

medications.

Ketones: Uncontrolled diabetes mellitus can lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous

Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders. Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.

Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retained in bladder prior to collection. pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food

can affect the pH of urine. Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and

proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus.

Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine.

Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia

THYROID PANEL, SERUMTriiodothyronine T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabolism, body temperature, and

heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (T5H), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of T5H.

Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is

hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3

Levels in TOTAL T4 TSH3G TOTAL T3 (µIU/mL) 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 Pregnancy First Trimester (µg/dL) 6.6 - 12.4 (ng/dL) 81 - 190 6.6 - 15.5 6.6 - 15.5 100 - 260 100 - 260 2nd Trimester 3rd Trimester

Below mentioned are the guidelines for age related reference ranges for T3 and T4.

T3 T4 (ng/dL) (µg/dL) 1-3 day: 8.2 - 19.9 1 Week: 6.0 - 15.9 New Born: 75 - 260

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing on the report under biological reference range.

- 1. Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.
  2. Gowenlock A.H. Varley's Practical Clinical Biochemistry, 6th Edition.
- 3. Behrman R.E. Kilegman R.M., Jenson H. B. Nelson Text Book of Pediatrics, 17th Edition ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.









**CLIENT CODE:** C000138364 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT **NEW DELHI 110030 DELHI INDIA** 8800465156

GRAND MALL, OPPOSITE SBI ZONAL OFFICE, SM ROAD, AMBAWADI,

PATIENT ID:

Biological Reference Interval

AHMEDABAD, 380015

GUJRAT, INDÍA

Tel: 079-48912999,079-48913999,079-48914999

Email: customercare.ahmedabad@srl.in

**PATIENT NAME: SAJANA KUMARI** 

SAJAF040692321

ACCESSION NO: 0321VG003216

<u>Final</u>

AGE: 30 Years

SEX: Female

ABHA NO: REPORTED:

25-07-2022 16:28

DRAWN:

RECEIVED: 23-07-2022 10:47

Results

CLIENT PATIENT ID:

Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

**ULTRASOUND ABDOMEN** 

**REFERRING DOCTOR: SELF** 

**Test Report Status** 

**ULTRASOUND ABDOMEN** ANTEVERTED UTERUS

\*\*End Of Report\*\*

Please visit www.srlworld.com for related Test Information for this accession

P. V. Capadia

**Dr.Priyank Kapadia Physician** 

Dr Kalpana Modi

Radiologist

Dr.Sahil .N.Shah **Consultant Radiologist** 

Dr.Miral Gajera Consultant Pathologist

#### **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All Tests are performed and reported as per the turnaround time stated in the SRL Directory of services (DOS).
- 3. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 4. A requested test might not be performed if:
- a. Specimen received is insufficient or inappropriate specimen quality is unsatisfactory
  - b. Incorrect specimen type
- c. Request for testing is withdrawn by the ordering doctor or patient
- d. There is a discrepancy between the label on the specimen container and the name on the test requisition form

- The results of a laboratory test are dependent on the quality of the sample as well as the assay technology.
- 6. Result delays could be because of uncontrolled circumstances. e.g. assay run failure.
- 7. Tests parameters marked by asterisks are excluded from the "scope" of NABL accredited tests. (If laboratory is accredited).
- 8. Laboratory results should be correlated with clinical information to determine Final diagnosis.
- 9. Test results are not valid for Medico- legal purposes. 10. In case of queries or unexpected test results please call at SRL customer care (Toll free: 1800-222-000). Post proper investigation repeat analysis may be carried out.

#### **SRL Limited**

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



